Form 4: Mineralys Therapeutics CEO Sells Over 15,000 Shares Under Pre-Arranged Trading Plan

Mineralys Therapeutics' CEO, Jon Congleton, executed a pre-scheduled sale of 15,884 common shares on July 11, 2025, as part of a Rule 10b5-1 trading plan.

Summary

• Jon Congleton, Chief Executive Officer, Director, and 10% Owner of Mineralys Therapeutics, Inc. (MLYS), sold 15,884 shares of common stock.
• The transaction occurred on July 11, 2025, at a weighted-average price of $14.5071 per share.
• The shares were sold in multiple transactions with prices ranging from $14.30 to $14.73.
• This sale was conducted pursuant to a Rule 10b5-1 trading plan adopted by Mr. Congleton on January 30, 2024.
• Following this transaction, Mr. Congleton directly beneficially owns 846,405 shares of common stock.

Sentiment

Score: 5

Explanation: Neutral. While an insider sale can be perceived negatively, the fact that it was conducted under a pre-arranged 10b5-1 plan mitigates immediate concerns about management's confidence in the company's short-term prospects.

Positives

• The sale was executed under a pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance and not a reaction to recent undisclosed negative company developments.
• The company's stock price range for the sale ($14.30 to $14.73) indicates a specific valuation at the time of the transaction.

Negatives

• The sale by a key executive, the Chief Executive Officer, reduces their direct ownership stake in the company.
• Insider selling, even if pre-planned, can sometimes be perceived negatively by investors as it might suggest a lack of confidence or a belief that the stock's upside is limited.

Risks

• Potential negative market perception or investor sentiment due to the insider sale, which could put downward pressure on the stock price.

Future Outlook

No explicit forward-looking statements or guidance are provided beyond the transaction details.

Management Comments

• The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2024.

Industry Context

This Form 4 filing details a routine insider stock transaction and does not provide information directly related to broader industry trends or competitive landscape.

Comparison to Industry Standards

• Not applicable, as this document reports a specific insider trading transaction rather than company performance metrics or project results that can be benchmarked against industry standards.

Related Party Transactions

• The sale of shares by the Chief Executive Officer to the open market constitutes a related party transaction.

Stakeholder Impact

• Shareholders may react to the news of an insider sale, potentially leading to short-term fluctuations in the stock price.

Next Steps

• No specific future actions or milestones are mentioned in this filing.

Key Dates

Recommendation

Keywords

Mineralys Therapeutics, MLYS, Jon Congleton, CEO, insider trading, Form 4, stock sale, 10b5-1 plan, common stock, beneficial ownership